September 9th 2025
In both trials, Beacon’s lead program, laru-zova, was found to be well-tolerated by SKYLINE participants through month 36 and DAWN patients at month 9 or longer.
September 9th 2025
FDA extends target action date for two Regeneron regulatory submissions to Q4 of 2025
August 21st 2025Included is the supplemental Biologics License Application (sBLA) for EYLEA HD seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week dosing across approved indications.
Read More
FDA clears IND for Opus Genetics’ OPGx-BEST1 gene therapy for inherited retinal disease
August 19th 2025Best disease, or vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by mutations in the BEST1 gene, leading to progressive vision loss and, in some cases, blindness.
Read More
Lupin and Sandoz sign licensing deal for biosimilar ranibizumab across multiple regions
August 13th 2025Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia under the terms of the agreement.
Read More
Study data show parental delay is biggest factor in late retinoblastoma diagnosis
August 12th 2025Ocular salvage and preservation of vision are essentially dependent on early diagnosis, and several studies have been conducted to identify the factors leading to delayed diagnosis at presentation.
Read More